ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.